🇺🇸 FDA
Patent

US 9371529

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

granted A61KA61K31/7105A61K31/713

Quick answer

US patent 9371529 (RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions) held by Arrowhead Research Corporation expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Research Corporation
Grant date
Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/7105, A61K31/713, A61P, A61P11/02